Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Treatment patterns and outcomes among warm autoimmune hemolytic anemia patients receiving rituximab in the United States: A retrospective database study

View Full Paper
Ask AI
Bookmark
Share

Authors

SFShannon FerranteLLLiang-Yuan LinZCZia Choudhry

Discussion

Loading...

Member takes

Overview

Retrospective cohort study reports relapse frequency and treatment patterns in patients with warm autoimmune hemolytic anemia receiving rituximab.

Key Points

  • To describe treatment patterns and relapse events among patients with warm autoimmune hemolytic anemia receiving rituximab.
  • Retrospective cohort study using HealthVerity data from January 2019 to June 2023
  • Inclusion criteria based on claims with ICD-10-CM codes for wAIHA
  • Analysis included treatment cycles and relapse episodes among RTX users
  • 380 out of 1,309 identified wAIHA patients received rituximab
  • 51.8% of patients experienced at least one relapse episode
  • 70 patients were hospitalized related to wAIHA during follow-up

Cite This Study

Ferrante et al. (2025) studied this question.

synapsesocial.com/papers/69362f6c4fa91c937236dfe8https://doi.org/10.1182/blood-2025-4459
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Heterogeneity of treatment regimens and related health resource use in managing patients with waiha: A US multi-database retrospective observational Study2025
  2. 2Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study2024 · 5 citations
  3. 3Effectiveness and safety of rituximab in severely relapsed antineutrophil cytoplasmic antibody–associated vasculitis: a retrospective analysis of a Japanese multicentre cohort from the J-CANVAS2024
  4. 4A Report on the Clinical Efficacy of Rituximab Administration in Patients with Inborn Errors of Immunity and Autoimmune/Autoinflammatory Manifestations2025
  5. 5Time to Relapse Following Rituximab Therapy in Rheumatoid Arthritis and Its Determinants: A Single-Center Observational Study2026